NCT00578071 - Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

June 30, 2012

Conditions

Cancer of the Esophagus

Interventions

DRUG

Panitumumab

Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.

DRUG

Capecitabine

Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation

DRUG

Oxaliplatin

Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation

RADIATION

Radiation Therapy (RT)

Daily for 6 weeks

Trial Locations (1)

Duke University Medical Center, Durham